ScreenerHero

SCYXSCYNEXIS, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · scynexis.com
5.100USD-0.97%Mkt Cap: 50.74M $P/E: —

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap50.74M $
Enterprise Value-201.04K $
Revenue (TTM)19.22M $
Gross Profit19.22M $
Net Income (TTM)-8.61M $
Revenue/Share2.496 USD
Last Price5.100 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS8112922005
Valuation
P/E (Trailing)—
P/E (Forward)-2.25
PEG—
EV/EBITDA—
EV/Revenue-0.01
P/S2.70
P/B0.78
EPS (TTM)-0.92
EPS (Forward)-2.31
52W Range
3.53023% of range10.48
52W High10.48 USD
52W Low3.530 USD
Profitability
Gross Margin100.00%
Oper. Margin-3308.51%
EBITDA Margin0.00%
Profit Margin-41.79%
ROE-17.44%
ROA-14.58%
Growth
Revenue Growth-82.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.28M $
CapEx (TTM)—
FCF Margin-38.11%
FCF Yield-14.43%
Net Debt-52.14M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.04
Current Ratio9.65
Quick Ratio9.29
Book Value/Sh6.727 USD
Cash/Share5.436 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 17, 2020
Splits
Last Split1:8
Split DateJun 1, 2026
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)36.55 USD
Upside (mean)+616.6%
Target Range32.00 USD – 44.64 USD
$32.00+616.6% to mean$44.64
# Analysts3
Ownership
Shares Out.9.95M
Float7.36M
Insiders1.99%
Institutions61.95%
Short Interest
Short Ratio1.6d
Short % Float3.49%
Short % Out.3.43%
Shares Short340.80K
Short (prev mo.)380.84K
Technical
SMA 504.425 (+15.2%)
SMA 2005.672 (-10.1%)
Beta1.10
S&P 52W Chg18.16%
Avg Vol (30d)192.59K
Avg Vol (10d)87.05K
Technical Indicators
RSI (14)57.5
MACD0.2015
MACD Signal0.1655
MACD Hist.+0.0360
BB Upper6.007 USD
BB Middle4.687 USD
BB Lower3.367 USD
BB Width56.31%
ATR (14)0.4010 USD
Vol Ratio (20d)0.13x